FrancophonIA/ELRC3.0 huggingface dataset:
English: Carbomer, colloidal silicon dioxide (E551), hypromellose (E464), lactose monohydrate, magnesium stearate (E572), methacrylic acid copolymer, macrogol, povidone (E1201), red iron oxide (E172), talc (E533b), titanium dioxide (E171)
Estonian: Karbomeer, kolloidne ränidioksiid (E551), hüpromelloos (E464), laktoosmonohüdraat, magneesiumstearaat (E572), metakrüülhappe kopolümeer, makrogool, polüvidoon (E1201), punane raudoksiid (E172), talk (E533b), titaandioksiid (E171)
English: If you take too much nifedipine a low blood pressure (hypertension) can occur, which can be recognised from symptoms like dizziness, nausea, vomiting, drowsiness, confusion, lethargy, flushing, a lack of oxygen (hypoxia), headache or red spots on the face.
Estonian: Madala vererõhu sümptomiteks on pearinglus, iiveldus, oksendamine, uimasus, segasus, unisus, näopunetus, õhupuudus (hüpoksia), peavalu või punetav lööve näol.
English: Read all of this leaflet carefully before you start taking using this medicine.
Estonian: Enne ravimi kasutamist lugege hoolikalt infolehte.
English: - moisture in lungs (pulmonary oedema) - fainting (syncope) - heart block - peeling or flaking of skin (exfoliative dermatitis) - severe blistering of the skin and/or mucous membranes of the lips, eyes, mouth, nasal passages or genitals (signs of Steven-Johnson syndrome) - skin rashes (erythema multifome, pemphigus, fixed drug eruption, urticaria) - reduced production of red blood cells (aplastic anaemia) - increase in blood potassium levels (when used together with another medicine called propranolol)
Estonian: (Steven-Johnson´i sündroom) - nahalööve (multiformne erüteem, villtõbi, ravimallergia, nõgestõbi) - punaste vererakkude vähenemine (aplastiline aneemia) - vere kaaliumi sisalduse tõus (kui nifedipiini kastutada koos propranolooliga)
English: angina upon abrupt withdrawal of nifedipine, increased frequency or worsening of angina, aggravation of myocardial ischemia including myocardial infarction, palpitations (tachycardia - accelerated pulse rate), congestive heart failure, hypotension, orthostatic hypotension.
Estonian: ravi järsul lõpetamisel stenokardia, stenokardiahoogude sagenemine või raskusastme süvenemine, südamelihase isheemia süvenemine (kaasa arvatud südamelihase infarkt), südamepekslemishood (tahhükardia), südame paispuudulikkus, hüpotensioon, ortostaatiline hüpotensioon.
English: Nervous system disorders: - Uncommon:
Estonian: Närvisüsteemi häired: - Aeg-ajalt:
English: HOW TO TAKE NIFEDIPINE PHARMAMATCH RETARD
Estonian: KUIDAS NIFEDIPINE PHARMAMATCH RETARD'I VÕTTA
English: gynaecomastia in men over 50 years; reversible at discontinuation of treatment.
Estonian: günekomastia üle 50-aastastel meestel, mis taandub nifedipiinravi lõpetamisel.
English: Use in breast-feeding mothers
Estonian: Kasutamine rinnaga toitvatel emadel
English: Other toxic effects include nausea, vomiting drowsiness, dizziness, confusion, lethargy, flushing, hypoxia, headache, red spots on the face, and unconsciousness to the point of coma
Estonian: segasusseisund, unisus, näopunetus, hüpoksia, peavalu, punane papulaarne lööve näol ja teadvusetus kuni koomani.
English: bezoars, gingival hyperplasia after long-term treatment, which recedes completely at discontinuation of nifedipine.
Estonian: Pikaajalise ravi järgselt võib tekkida igemete hüperplaasia, mis taandub pärast nifedipiinravi lõpetamist.
English: What Nifedipine Pharmamatch retard contains
Estonian: Mida Nifedipine Pharmamatch retard sisaldab:
English: For hypertension:
Estonian: Hüpertensiooni ravi
English: - The other ingredients are: carbomer, colloidal silicon dioxide (E551), hypromellose (E464), lactose monohydrate, magnesium stearate (E572), methacrylic acid copolymer, macrogol, povidone (E1201), red iron oxide (E172), talc (E533b) and titanium dioxide (E171).
Estonian: - Abiained on: karbomeer, kolloidne ränidioksiid (E551), hüpromelloos (E464), laktoosmonohüdraat, magneesiumstearaat (E572), metakrüülhappe kopolümeer, makrogool, polüvidoon (E1201), punane raudoksiid (E172), talk (E533b), titaandioksiid (E171).
English: If the dose of nifedipine is increased during co-administration of both medicines, a reduction of the nifedipine dose should be considered when the treatment with phenytoin is discontinued.
Estonian: Kui nifedipiini annust tõstetakse fenütoiini ravi foonil, tuleb fenütoiini ravi lõpetamisel nifedipiini annust langetada.
English: In studies in mice, rats and rabbits, a dose which was maternally toxic induced teratogenic effects in some cases and embryotoxicity.
Estonian: Hiirtel, rottidel ja küülikutel läbiviidud loomkatsetes on ilmnenud kahjulik toime reproduktiivsusele, embrüole ja loote arengule.
English: Each tablet contains: 60 mg nifedipine
Estonian: TOIMEAINE(TE) SISALDUS Iga tablett sisaldab: 60 mg nifedipiini.
English: Nifedipine Pharmamatch retard will not prevent possible rebound effects after cessation of other antihypertensive therapy.
Estonian: Nifedipine Pharmamatch retard tabletid ei hoia ära teiste vererõhku alandavate preparaatidega ravi katkestamise järgselt tekkivat vererõhu tõusu.
English: RVG 31822 - Nifedipine Pharmamatch retard 30 mg, prolonged-release tablets
Estonian: MÜÜGILOA NUMBER(NUMBRID) RVG 31822 - Nifedipine Pharmamatch retard 30 mg toimeainet prolongeeritult vabastavad tabletid.
English: Separate analysis of the individual end-points show little differences in incidence between the groups treated with nifedipine or diuretics of stroke (2.0% versus 2.3%), MI (2.9% versus 2.7%) and death caused by any other cardiovascular disease (0.4% versus 0.4%).
Estonian: Müokardiinfarkti esines vastavalt 2,9% ja 2,7% ning letaalset lõpet mõne muu kardioloogilise komplikatsiooni tulemusena 0,4% ja 0,4%.
English: - if you have a severe narrowing of the gastrointestinal tract.
Estonian: Nimetatud süsteem on esindatud gastrointestinaaltrakti limaskestas ja maksas.
English: Rare (more than 1 out of 10.000, but less than 1 out of 1.000 patients): - skin rash - muscle cramps - inflammation of the gums - a mass of foreign material found in the stomach (bezoar) - a slight development in breast tissue in older men (gynaecomastia)
Estonian: Harva (rohkem kui ühel patsiendil kümnest tuhandest, kuid vähem kui ühel patsiendil tuhandest): - nahalööve - lihasekrambid - igemete turse - sooltes tekkinud seedimatu taimekiududest pallitaoline moodustis (besoaar) - rinnanäärmete arenemine vanematel meestel (günekomastia)
English: The safety of nifedipine during pregnancy has not been established.
Estonian: Nifedipiini ohutuse kohta rasedatel ei ole piisavalt andmeid.
English: The incidence of heart failure shows a difference between both treatments (0.9% versus 0.3%).
Estonian: Südamepuudulikkust esines nifedipiini grupis 0,9% ja diureetikumide grupis 0,3%.
English: Very common (more than 1 out of 10 patients): - headache - flushing - swelling, particularly of the ankles and legs
Estonian: Väga sageli (rohkem kui ühel patsiendil kümnest): - peavalu - näo punetus - turse jalgadel, eriti hüppeliigeste piirkonnas - peapööritus - uimasus - rõhutunne peas
English: Phenytoin induces the CYP3A4 system.
Estonian: Fenütoiin on CYP3A4 süsteemi indutseerija.
English: aplastic anaemia, increase in serum potassium when nifedipine is combined with propranolol.
Estonian: aplastiline aneemia, nifedipiini ja propranolooli koosmanustamisel kaaliumi kontsentratsiooni tõus.
English: - Common:
Estonian: - Sage:
English: However, plasmaferesis can be recommended (high plasma protein-binding, relatively small volume of distribution).
Estonian: Nifedipiini üleannustamise korral võib soovitada plasmafereesi, kuna nifedipiinil on kõrge afiinsus plasmaproteiinide suhtes ning suhteliselt väike jaotuvusruumala.
English: Coadministered of the mentioned medicines with nifedipine can be expected to lead to a substantial increase in bioavailability of nifedipine, due to a decreased first pass metabolism and decreased elimination.
Estonian: Erütromütsiini, fluoksetiini ja proteaasi inhibiitorite manustamisel koos nifedipiiniga võiks oodata nifedipiini biosaadavuse suurenemist esimese maksapassaaži metabolismi tõusu tõttu ning eliminatsiooni vähenemist.
English: Preclinical data revela no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.
Estonian: Tavapärased farmakoloogilise ohutuse, kroonilise toksilisuse, genotoksilisuse ja kartsinogeensuse prekliinilised uuringud ei ole näidanud kahjulikku toimet.
English: Musculoskeletal and connective tissue disorders: - Rare:
Estonian: Lihas-skeleti ja sidekoe kahjustused: - Harv:
English: You should not use Nifedipine Pharmamatch retard for secondary prevention of a heart attack.
Estonian: Nifedipiini ei kasutata müokardi infarkti sekundaarseks preventsiooniks.
English: For the treatment of all grades of hypertension.
Estonian: Hüpertensiooni ravi olenemata raskusastmest.
English: If you have any further questions on the use of this product, ask your doctor or pharmacist.
Estonian: Kui teil on lisaküsimusi, pidage nõu oma arsti või apteekriga.
English: Important information about some of the ingredients of Nifedipine Pharmamatch retard
Estonian: Oluline teave mõne Nifedipine Pharmamatch retard'i koostisaine suhtes Nifedipine Pharmamatch retard tabletid sisaldavad laktoosi.
English: Rifampicin strongly induces the CYP3A4 system.
Estonian: Rifampitsiin on tugev CYP3A4 süsteemi indutseerija.
English: In patients with hepatic impairment careful monitoring is required and, in severe cases, a lowering of the dose may be necessary.
Estonian: Maksapuudulikkus Maksafunktsioonihäirega patsientidel tuleb ravi hoolikalt jälgida ning vajadusel annust vähendada.
English: Each tablet contains: 30 mg nifedipine
Estonian: TOIMEAINE(TE) SISALDUS Iga tablett sisaldab: 30 mg nifedipiini.
English: However, if it is already almost time to take the next dose (i.e. you skipped one day), skip the missed dose and continue to take the medicine according to the normal dosage scheme.
Estonian: Kui olete vahele jätnud terve päeva, võtke järgmine annus tavalisel ajal.
English: It is not known if a pharmacological effect in the infant can occur because of this; however, it is recommended to cease breast feeding as a precautionary measure.
Estonian: Ei ole teada, kas rinnapiimas olev ravim avaldab farmakoloogilist toimet imikule.
English: Carbamazepine, phenobarbitone and valproic acid Some substances have been shown to influence the plasma concentration of the structurally related calcium antagonist nimodipine, either by enzyme induction (carbamazepine, phenobarbitone) or enzyme inhibition (valproic acid).
Estonian: Mõjutused avalduvad kas ensüümi induktsiooni (karbamasepiin, fenobarbitaal) või ensüümi inhibitsiooni (valproehape) kaudu.
English: In case of concomitant use of both medicines, blood pressure should be monitored and, if necessary, a reduction in the nifedipine dose considered.
Estonian: Kui nimetatud ravimeid manustatakse üheaegselt, peab jälgima patsiendi vererõhku ja vajadusel vähendama nifedipiini annust.
English: Diabetic patients who use Nifedipine Pharmamatch retard may require adjustment of their control.
Estonian: Diabeetikud, kes kasutavad Nifedipine Pharmamatch retard tablette, peaksid hoolikalt jälgima oma veresuhkru taset ning vajadusel diabeedi ravi kohandama.
English: constipation, nausea.
Estonian: kopsuturse, minestamine, südameblokaad.
English: Some studies reveal increased plasma concentrations of nifedipine in case of co-administration with quinidine, though others revealed no effects on the pharmacokinetic properties of nifedipine.
Estonian: Osades uuringutes aga ei ole kinidiini toime nifedipiini farmakokineetilistele omadustele leidnud kinnitust.
English: Especially for prolonged-release products (Nifedipine Pharmamatch retard) elimination must be as complete as possible, including the small intestine, to prevent the otherwise inevitable subsequent absorption of the active substance.
Estonian: Toimeainet aeglaselt vabastavate ravimite eemaldamine organismist peab toimuma nii põhjalikult kui võimalik.
English: Eye disorders: - Uncommon:
Estonian: Silmakahjustused: - Aeg-ajalt:
English: Increased or decreased heart rates are also a symptom of overdosage.
Estonian: Üleannustamise sümptomiteks on väga kiire või aeglane südamelöögisagedus.
English: In case of concomitant use, blood pressure should be monitored and, if necessary, a reduction in the nifedipine dose considered.
Estonian: Ravimite manustamisel peab hoolikalt jälgima patsiendi vererõhku ning vajadusel vähendama nifedipiini annust.
English: Elimination of the active substance and the restoration of stable cardiovascular conditions have priority.
Estonian: Kui ravimit on manustatud suukaudselt, on esmaabiks maoloputus ja eluliste funktsioonide tagamine (stabiliseerida südameveresoonkonna seisund).
English: Medicines that do not influence Nifedipine Pharmamatch retard or are not influenced by Nifedipine Pharmamatch retard.
Estonian: Ravimid, mis ei oma koostoimeid Nifedipine Pharmamatch retard tablettidega
English: In individual cases, when used in combination with nifedipine, serum quinidine levels have been shown to be suppressed or, after cessation of nifedipine treatment, increased.
Estonian: Üksikutel juhtudel on kinidiini ja nifedipiini kombinatsiooni kasutamisel vähenenud kinidiini kontsentratsioon seerumis.
English: Round, biconvex tablets with a pale red colour.
Estonian: Ümmargused, kaksikkumerad, heleroosad tabletid.
English: In case of co-administration of nifedipine with β-blocking medicines, the patient should be carefully monitored, since severe hypotension can occur.
Estonian: Kui nifedipiini kasutada koos beetablokaatoritega, tuleb patsienti hoolikalt jälgida.
English: Cardiac effects may include heart block, AV dissociation and asystole, and cardiogenic shock with pulmonary oedema.
Estonian: kardiovaskulaarne šokk, millega kaasneb kopsuturse.
English: Nifedipine is almost entirely metabolised (> 90%); approximately 70-80% is excreted in urine.
Estonian: Ligikaudu 70...80% manustatud ravimist eritatakse uriiniga.
English: HOW TO STORE NIFEDIPINE PHARMAMATCH RETARD
Estonian: Kuidas Nifedipine Pharmamatch retard'i säilitada Lisainfo
English: Nifedipine Pharmamatch retard 30 mg, prolonged-release tablets contain 30 mg nifedipine per tablet.
Estonian: Iga Nifedipine Pharmamatch retard 30 mg toimeainet prolongeeritult vabastav tablett sisaldab 30 mg nifedipiini.
English: Therefore, monitoring of quinidine plasma levels is recommended.
Estonian: Kirjeldatud vastastikmõju tõttu on soovitatav kinidiini ja nifedipiini koosmanustamisel jälgida kinidiini plasmakontsentratsiooni.
English: Caution should be exercised when nifedipine is co-administered with intravenous magnesium sulphate.
Estonian: Intravenoosse magneesiumsulfaadi ja nifedipiini koosmanustamisel peab olema väga ettevaatlik.
English: Nifedipine can worsen an existing decompensatio cordis.
Estonian: Nifedipiin võib halvendada olemasolevat südamepuudulikkust; - kui teil on kõhulahtisus.
English: Bioavailability is approximately
Estonian: Biosaadavus on ligikaudu 40...60%.
English: In vitro fertilisation
Estonian: Kunstlik viljastamine
English: Nifedipine Pharmamatch retard tablets must not be prescribed for these patients.
Estonian: Enne Nifedipine Pharmamatch retard tablettide manustamist ei ole soovitav greibimahla juua.
English: Medicines that are known to either inhibit or induce this enzyme can therefore alter the absorption (after oral administration) or elimination of nifedipine.
Estonian: Ravimid, mis inhibeerivad või indutseerivad ensüümi CYP3A4 võivad mõjutada suukaudse nifedipiini imendumist või elimineerumist.
English: Nifedipine Pharmamatch retard 60 mg, prolonged-release tablets contain 60 mg nifedipine per tablet.
Estonian: Iga Nifedipine Pharmamatch retard 60 mg toimeainet prolongeeritult vabastav tablett sisaldab 30 mg nifedipiini.
English: - giddiness - light headedness - feeling of pressure in the head.
Estonian: peavalu, peapööritus, uimasus, survetunne peas.
English: NAME OF THE MEDICINAL PRODUCT Nifedipine Pharmamatch retard 60 mg prolonged-release tablets Nifedipine.
Estonian: RAVIMPREPARAADI NIMETUS Nifedipine Pharmamatch retard 60 mg toimeainet prolongeeritult vabastavad tabletid.
English: NAME OF THE MEDICINAL PRODUCT Nifedipine Pharmamatch retard 30 mg prolonged-release tablets Nifedipine.
Estonian: RAVIMPREPARAADI NIMETUS Nifedipine Pharmamatch retard 30 mg toimeainet prolongeeritult vabastavad tabletid.
English: - if you experience severe chest pains, or if the chest pains worsen.
Estonian: Nifedipiin võib süvendada verevarustuse puudulikkust; - kui teil on tugevaid valusid rinnus või kui need valud pidevalt süvenevad.
English: It is not recommended to drink grapefruit juice when treated with Nifedipine Pharmamatch retard.
Estonian: Patsientidel, kellel on diagnoositud ahenemine soolestikus, ei ole soovitatav kasutada Nifedipine Pharmamatch retard tablette.
English: A small fraction of nifedipine passes into the breast milk.
Estonian: Nifedipiin eritub väikeses koguses rinnapiima.
English: Symptoms of obstruction have also been seen in patients in which no gastrointestinal narrowing was diagnosed.
Estonian: Nifedipine Pharmamatch retard tablettide kasutamise ajal on täheldatud gastrointestinaaltrakti obstruktsiooninähte ka patsientidel, kellel ei ole diagnoositud soolte ahenemist või obstruktsiooni.
English: Subsequent titration to a higher dose may be initiated as warranted clinically
Estonian: Soole ahenemise üheks sümptomiks võib olla kõhukinnisus.
English: In patients with possible hyperglycaemia, nifedipine should be given with caution.
Estonian: Nifedipiini peab manustama ettevaatusega patsientidele, kellel on oht hüperglükeemiaks.
English: Cardiovascular disorders:
Estonian: Südame-veresoonkonna häired: - Väga sage:
English: Dosage
Estonian: Ravi
English: Nifedipine can cause dizziness, headache, fatigue or nausea, especially at the beginning of therapy, after a change in your medication or when consumed with alcohol.
Estonian: Mõnedel patsientidel võib ravi alguses, ühelt ravimilt teisele üleminekul või koosmõjus alkoholiga tekkida pearinglust, peavalu, väsimust või iiveldust.
English: pulmonary oedema, syncope, heart block.
Estonian: silmaümbruse turse, kõrvade kumisemine.
English: Grapefruit juice inhibits the CYP3A4 system.
Estonian: Greibimahl pärsib CYP3A4 süsteemi.
English: Metabolic disturbances include hyperglycaemia, metabolic acidosis and hypo- or hyperkalaemia.
Estonian: Karbamasepiin, fenobarbitaal ja valproehape
English: BEFORE YOU TAKE NIFEDIPINE PHARMAMATCH
Estonian: MIDA ON VAJA TEADA ENNE NIFEDIPINE PHARMAMATCH RETARD'I VÕTMIST
English: Nifedipine can further lower the blood pressure.
Estonian: Nifedipiin võib vererõhku veelgi langetada; - kui teil on diabeet.
English: - Keep this leaflet.
Estonian: Hoida originaal mahutis.
English: Each prolonged release tablet contains 60 mg nifedipine.
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Iga toimeainet prolongeeritult vabastav tablett sisaldab 60 mg nifedipiini.
English: - if you have a low blood pressure (hypotension).
Estonian: Nifedipiini üleannustamisel võib tekkida tugev vererõhu langus (hüpotensioon).
English: 4.4 Special warnings and special precautions for use In exceptional cases, the use of nifedipine can lead to severe complaints of angina pectoris, probably due to fast resorption and an overly abrupt decrease in blood pressure.
Estonian: Harvadel juhtudel võib nifedipiini kasutamine ravimi kiire imendumise ja liiga järsu vererõhu languse tõttu kutsuda esile raskekujulisi stenokardia sümptomeid.
English: If necessary, the nifedipine dosage should be reduced (see also subsection ‘Effects of Nifedipine Pharmamatch retard on other active substances').
Estonian: (vt ka alapunkt „Nifedipine Pharmamatch retard tablettide toime teistele ravimitele”)
English: 6.4 Special precautions for storage Store in the original package.
Estonian: 6.4 Säilitamise eritingimused
English: Member State
Estonian: Ühendkuningriik
English: RVG 31823 - Nifedipine Pharmamatch retard 60 mg, prolonged-release tablets DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 29 November 2004
Estonian: MÜÜGILOA NUMBER(NUMBRID) RVG 31823 - Nifedipine Pharmamatch retard 60 mg toimeainet prolongeeritult vabastavad tabletid.
English: In such an event, you should stop taking Nifedipine Pharmamatch retard and contact your doctor.
Estonian: Sellisel juhul peaksite te lõpetama Nifedipine Pharmamatch retard tablettide võtmise ja pidama nõu oma arstiga; - kui teie südame väljutusjõud on ebapiisav (südamepuudulikkus).
English: Nifedipine Pharmamatch retard contains lactose.
Estonian: Kuidas Nifedipine Pharmamatch retard välja näeb ja pakendi sisu
English: However, the study involved a small number of patients and additional data are required.
Estonian: Sellegipoolest osales uuringus väike arv patsiente ja vaja on lisaandmeid.
English: The recommended dose is 350 mg once every 3 weeks.
Estonian: Soovitatav annus on 350 mg üks kord iga 3 nädala järel.
English: Further information on Libtayo can be found on the Agency's website: www.ema.europa.eu/medicines/human/EPAR/libtayo.
Estonian: Lisateave Libtayo kohta on ameti veebilehel: www.ema.europa.eu/medicines/human/EPAR/libtayo.
English: Libtayo (cemiplimab)
Estonian: Libtayo (tsemiplimaab)
English: What measures are being taken to ensure the safe and effective use of Libtayo?
Estonian: Mis meetmed võetakse, et tagada Libtayo ohutu ja efektiivne kasutamine?
English: The European Medicines Agency therefore decided that Libtayo's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Libtayo kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Treatment can continue for as long as the disease remains stable and the patient does not experience unacceptable side effects.
Estonian: Ravi tohib jätkata seni, kuni haigus püsib stabiilsena ja patsiendil ei teki vastuvõetamatuid kõrvalnähte.
English: What is Libtayo and what is it used for?
Estonian: Mis on Libtayo ja milleks seda kasutatakse?
English: In a main study involving a total of 193 patients, the cancer shrank in around 39% of patients with metastatic disease who received 350 mg Libtayo every 3 weeks for around one year.
Estonian: Põhiuuringus, milles osales 193 patsienti, vähenes kasvaja ligikaudu 39%-l metastaatilise haigusega patsientidest, kes said 350 mg Libtayot iga 3 nädala järel ligikaudu ühe aasta jooksul.
English: As for the medicine's safety, its side effects are manageable and similar to those seen in other cancer treatments of this type.
Estonian: Ravimi ohutuse seisukohast on selle kõrvalnähud hallatavad ja sarnased muude seda tüüpi vähiravimite kõrvalnähtudega.
English: It is used in patients who cannot have surgery or treatment with radiation to cure their disease.
Estonian: Seda kasutatakse patsientidel, kellele ei sobi kirurgiline või kiiritusravi.
English: As for all medicines, data on the use of Libtayo are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Libtayo kasutamise kohta pidevat järelevalvet.
English: The most common immune-related effects (which may affect up to 1 in 10 people) were hypothyroidism (an underactive thyroid gland with tiredness, weight gain, and skin and hair changes), pneumonitis (inflammation in the lungs causing shortness of breath and cough), skin reactions, hyperthyroidism (an overactive thyroid gland which can cause hyperactivity, sweating, weight loss and thirst) and hepatitis (inflammation of the liver).
Estonian: Kõige sagedamad immuunsüsteemiga seotud kõrvalnähud (võivad esineda kuni 1 patsiendil 10st) olid hüpotüreoos (kilpnäärme alatalitlus koos väsimuse, kaalutõusu ning naha- ja juuste muutustega), pneumoniit (kopsupõletik, mis põhjustab raskendatud hingamist ja köha), nahareaktsioonid, hüpertüreoos (kilpnäärme liigtalitlus, mis võib põhjustada hüperaktiivsust, higistamist, kaalukaotust ja janu) ning hepatiit (maksapõletik).
English: Side effects reported with Libtayo are carefully evaluated and any necessary action taken to protect patients.
Estonian: Libtayo kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.